Browse DUSP6

Summary
SymbolDUSP6
Namedual specificity phosphatase 6
Aliases MKP-3; PYST1; HH19; MKP3; MAP kinase phosphatase 3; dual specificity protein phosphatase PYST1; mitogen-acti ......
Chromosomal Location12q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF00782 Dual specificity phosphatase
PF00581 Rhodanese-like domain
Function

Inactivates MAP kinases. Has a specificity for the ERK family (PubMed:9858808). Plays an important role in alleviating chronic postoperative pain. Necessary for the normal dephosphorylation of the long-lasting phosphorylated forms of spinal MAPK1/3 and MAP kinase p38 induced by peripheral surgery, which drives the resolution of acute postoperative allodynia (By similarity). Also important for dephosphorylation of MAPK1/3 in local wound tissue, which further contributes to resolution of acute pain (By similarity).

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0000188 inactivation of MAPK activity
GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0001708 cell fate specification
GO:0001711 endodermal cell fate commitment
GO:0001714 endodermal cell fate specification
GO:0001933 negative regulation of protein phosphorylation
GO:0003002 regionalization
GO:0006469 negative regulation of protein kinase activity
GO:0006470 protein dephosphorylation
GO:0007369 gastrulation
GO:0007389 pattern specification process
GO:0007492 endoderm development
GO:0007507 heart development
GO:0008543 fibroblast growth factor receptor signaling pathway
GO:0009953 dorsal/ventral pattern formation
GO:0010453 regulation of cell fate commitment
GO:0010470 regulation of gastrulation
GO:0016311 dephosphorylation
GO:0032147 activation of protein kinase activity
GO:0033673 negative regulation of kinase activity
GO:0033674 positive regulation of kinase activity
GO:0035265 organ growth
GO:0035335 peptidyl-tyrosine dephosphorylation
GO:0035987 endodermal cell differentiation
GO:0040036 regulation of fibroblast growth factor receptor signaling pathway
GO:0042326 negative regulation of phosphorylation
GO:0042493 response to drug
GO:0042659 regulation of cell fate specification
GO:0042663 regulation of endodermal cell fate specification
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043407 negative regulation of MAP kinase activity
GO:0043409 negative regulation of MAPK cascade
GO:0043410 positive regulation of MAPK cascade
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0045165 cell fate commitment
GO:0045860 positive regulation of protein kinase activity
GO:0045995 regulation of embryonic development
GO:0046620 regulation of organ growth
GO:0048638 regulation of developmental growth
GO:0051348 negative regulation of transferase activity
GO:0051409 response to nitrosative stress
GO:0060419 heart growth
GO:0060420 regulation of heart growth
GO:0060795 cell fate commitment involved in formation of primary germ layer
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070373 negative regulation of ERK1 and ERK2 cascade
GO:0071774 response to fibroblast growth factor
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0090287 regulation of cellular response to growth factor stimulus
GO:1902532 negative regulation of intracellular signal transduction
GO:1903224 regulation of endodermal cell differentiation
Molecular Function GO:0004721 phosphoprotein phosphatase activity
GO:0004725 protein tyrosine phosphatase activity
GO:0008138 protein tyrosine/serine/threonine phosphatase activity
GO:0016791 phosphatase activity
GO:0017017 MAP kinase tyrosine/serine/threonine phosphatase activity
GO:0033549 MAP kinase phosphatase activity
GO:0042578 phosphoric ester hydrolase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
Reactome R-HSA-170984: ARMS-mediated activation
R-HSA-166054: Activated TLR4 signalling
R-HSA-422475: Axon guidance
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-186763: Downstream signal transduction
R-HSA-198753: ERK/MAPK targets
R-HSA-202670: ERKs are inactivated
R-HSA-2871796: FCERI mediated MAPK activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-170968: Frs2-mediated activation
R-HSA-179812: GRB2 events in EGFR signaling
R-HSA-881907: Gastrin-CREB signalling pathway via PKC and MAPK
R-HSA-2428924: IGF1R signaling cascade
R-HSA-112399: IRS-mediated signalling
R-HSA-2428928: IRS-related events triggered by IGF1R
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-74751: Insulin receptor signalling cascade
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-450294: MAP kinase activation in TLR cascade
R-HSA-5683057: MAPK family signaling cascades
R-HSA-450282: MAPK targets/ Nuclear events mediated by MAP kinases
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-375165: NCAM signaling for neurite out-growth
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-5675221: Negative regulation of MAPK pathway
R-HSA-198725: Nuclear Events (kinase and transcription factor activation)
R-HSA-169893: Prolonged ERK activation events
R-HSA-112409: RAF-independent MAPK1/3 activation
R-HSA-5673001: RAF/MAP kinase cascade
R-HSA-8853659: RET signaling
R-HSA-180336: SHC1 events in EGFR signaling
R-HSA-112412: SOS-mediated signalling
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-74752: Signaling by Insulin receptor
R-HSA-449147: Signaling by Interleukins
R-HSA-2586552: Signaling by Leptin
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-2404192: Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
R-HSA-194138: Signaling by VEGF
R-HSA-166520: Signalling by NGF
R-HSA-187687: Signalling to ERKs
R-HSA-167044: Signalling to RAS
R-HSA-187706: Signalling to p38 via RIT and RIN
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218921: VEGFR2 mediated cell proliferation
Summary
SymbolDUSP6
Namedual specificity phosphatase 6
Aliases MKP-3; PYST1; HH19; MKP3; MAP kinase phosphatase 3; dual specificity protein phosphatase PYST1; mitogen-acti ......
Chromosomal Location12q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DUSP6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolDUSP6
Namedual specificity phosphatase 6
Aliases MKP-3; PYST1; HH19; MKP3; MAP kinase phosphatase 3; dual specificity protein phosphatase PYST1; mitogen-acti ......
Chromosomal Location12q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DUSP6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 2.83; FDR: 0.000150 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolDUSP6
Namedual specificity phosphatase 6
Aliases MKP-3; PYST1; HH19; MKP3; MAP kinase phosphatase 3; dual specificity protein phosphatase PYST1; mitogen-acti ......
Chromosomal Location12q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DUSP6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.120.814
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1030.973
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1190.954
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1990.66
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6590.754
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3820.886
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2980.613
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.7740.718
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3010.895
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8480.544
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5280.469
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5260.000323
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DUSP6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.407.40.0709
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.407.40.096
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDUSP6
Namedual specificity phosphatase 6
Aliases MKP-3; PYST1; HH19; MKP3; MAP kinase phosphatase 3; dual specificity protein phosphatase PYST1; mitogen-acti ......
Chromosomal Location12q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DUSP6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDUSP6
Namedual specificity phosphatase 6
Aliases MKP-3; PYST1; HH19; MKP3; MAP kinase phosphatase 3; dual specificity protein phosphatase PYST1; mitogen-acti ......
Chromosomal Location12q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DUSP6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DUSP6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDUSP6
Namedual specificity phosphatase 6
Aliases MKP-3; PYST1; HH19; MKP3; MAP kinase phosphatase 3; dual specificity protein phosphatase PYST1; mitogen-acti ......
Chromosomal Location12q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DUSP6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDUSP6
Namedual specificity phosphatase 6
Aliases MKP-3; PYST1; HH19; MKP3; MAP kinase phosphatase 3; dual specificity protein phosphatase PYST1; mitogen-acti ......
Chromosomal Location12q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DUSP6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDUSP6
Namedual specificity phosphatase 6
Aliases MKP-3; PYST1; HH19; MKP3; MAP kinase phosphatase 3; dual specificity protein phosphatase PYST1; mitogen-acti ......
Chromosomal Location12q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DUSP6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDUSP6
Namedual specificity phosphatase 6
Aliases MKP-3; PYST1; HH19; MKP3; MAP kinase phosphatase 3; dual specificity protein phosphatase PYST1; mitogen-acti ......
Chromosomal Location12q22-q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DUSP6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.